The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
Open accessAbstract
We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). This was a multicentre, randomised, double-blind, placebo- and active-controlled, 26-week trial. Patients (n = 2144) were randomised (2:2:2:2:1) to receive once-daily QVA149 (indacaterol 110 μg/glycopyrronium 50 μg), indacaterol 150 μg, glycopyrronium 50 μg, open-label tiotropium 18 μg or placebo. The primary end-point was trough forced expiratory volume in 1 s (FEV 1) at week 26 for QVA149 versus its monocomponents. Secondary end-points included dyspnoea, health status, rescue medication use and safety. Trough FEV 1 at week 26 was significantly improved (p<0.001) with QVA149 compared with indacaterol and glycopyrronium (least squares mean (LSM) differences 0.07 L and 0.09 L, respectively), tiotropium and placebo (LSM differences 0.08 L and 0.20 L, respectively); these beneficial effects were sustained throughout the 26-week study. QVA149 significantly improved dyspnoea and health status versus placebo (p<0.001 and p = 0.002, respectively) and tiotropium (p = 0.007 and p = 0.009, respectively) at week 26. All treatments were well tolerated. Dual bronchodilation with once-daily QVA149 demonstrated superior and clinically meaningful outcomes versus placebo and superiority versus treatment with a single bronchodilator, with a safety and tolerability profile similar to placebo, supporting the concept of fixed-dose long-acting muscarinic antagonist/long-acting β 2-agonist combinations for the treatment of COPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., & HURD, S. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2101039 · Cited by 6,587
Global Initiative for Chronic Obstructive Lung Disease
Gerald, L. B., & Bailey, W. C. (2002) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200207000-00004 · Cited by 5,830
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
Self-citationCardiovascular Effects of β-Agonists in Patients With Asthma and COPD
Salpeter, S. R., Ormiston, T. M., & Salpeter, E. E. (2004) · Chest · doi:10.1378/chest.125.6.2309 · Cited by 560
Wedzicha, J. A., Decramer, M., Ficker, J. H., Niewoehner, D. E., Sandström, T., Taylor, A. F., D'Andrea, P., Arrasate, C., Chen, H., & Banerji, D. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70052-3 · Cited by 535
Self-citationDecramer, M., Celli, B., Kesten, S., Lystig, T., Mehra, S., & Tashkin, D. P. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61298-8 · Cited by 495
Bourbeau, J., & Bartlett, S. J. (2008) · Thorax · doi:10.1136/thx.2007.086041 · Cited by 490 · cited 1×
“Features of QVA149 that may help to reduce non-adherence to treatment, which remains high in COPD [26] are the convenience of once-daily dosing [27] which is generally preferred by patients [26, 28, 29] and the need for only one single inhaler.”
Backgroundvan Noord, J. A., Aumann, J.-L., Janssens, E., Smeets, J. J., Verhaert, J., Disse, B., Mueller, A., & Cornelissen, P. J. G. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00140404 · Cited by 341
Vogelmeier, C. F., Bateman, E. D., Pallante, J., Alagappan, V. K., D'Andrea, P., Chen, H., & Banerji, D. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(12)70052-8 · Cited by 314
Self-citationTreatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs
Toy, E. L., Beaulieu, N. U., McHale, J. M., Welland, T. R., Plauschinat, C. A., Swensen, A., & Duh, M. S. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2010.09.006 · Cited by 281
Loke, Y. K., Cavallazzi, R., & Singh, S. (2011) · Thorax · doi:10.1136/thx.2011.160028 · Cited by 267
Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis
Barr, R. G. (2006) · Thorax · doi:10.1136/thx.2006.063271 · Cited by 236
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Kerwin, E., Hébert, J., Gallagher, N., Martin, C., Overend, T., Alagappan, V. K. T., Lu, Y., & Banerji, D. (2012) · European Respiratory Journal · doi:10.1183/09031936.00040712 · Cited by 210
Self-citationEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
D'Urzo, A., Ferguson, G. T., van Noord, J. A., Hirata, K., Martin, C., Horton, R., Lu, Y., Banerji, D., & Overend, T. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-156 · Cited by 176
Self-citationFormoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study
Vogelmeier, C., Kardos, P., Harari, S., Gans, S. J. M., Stenglein, S., & Thirlwell, J. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.07.020 · Cited by 172
Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD
Tashkin, D. P., Pearle, J. L., Iezzoni, D. G., & Varghese, S. T. (2009) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550902724073 · Cited by 139
Inhaled ??2-Adrenoceptor Agonists
Cazzola, M., Matera, M. G., & Donner, C. F. (2005) · Drugs · doi:10.2165/00003495-200565120-00001 · Cited by 135
Beeh, K. M., Singh, D., Scala, D., & Drollmann (2012) · International Journal of COPD · doi:10.2147/copd.s32451 · Cited by 132
Rabe, K. F., Timmer, W., Sagkriotis, A., & Viel, K. (2008) · CHEST Journal · doi:10.1378/chest.07-2138 · Cited by 125
Mahler, D. A., D'Urzo, A., Bateman, E. D., Özkan, S. A., White, T., Peckitt, C., Lassen, C., Kramer, B., & on behalf of the INTRUST-1 and INTRUST-2 study investigators (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201140 · Cited by 105
Self-citationEnhanced persistence with tiotropium compared with other respiratory drugs in COPD
Postma, N. S., Koerselman, J., Erkens, J. A., Lammers, J. J., & Herings, R. M. C. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.01.025 · Cited by 72
Tashkin, D. P., Donohue, J. F., Mahler, D. A., Huang, H., Goodwin, E., Schaefer, K., Hanrahan, J. P., & Andrews, W. T. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.12.014 · Cited by 68
Measuring the effects of COPD on the patient
Jones, P., Lareau, S. C., & Mahler, D. A. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.09.011 · Cited by 66
Partridge, M. R., Miravitlles, M., Ståhl, E., Karlsson, N., Svensson, K., & Welte, T. (2009) · European Respiratory Journal · doi:10.1183/09031936.00123709 · Cited by 62
Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD
Berton, D. C., Reis, M., Siqueira, A. C. B., Barroco, A. C., Takara, L. S., Bravo, D. M., Andreoni, S., & Neder, J. A. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.05.017 · Cited by 46
Cited by
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
Wedzicha, J. A., Banerji, D., Chapman, K. R., Vestbo, J., Roche, N., Ayers, R. T., Thach, C., Fogel, R., Patalano, F., & Vogelmeier, C. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516385 · Cited by 844
Self-citationSingh, D., Papi, A., Corradi, M., Pavlišová, I., Montagna, I., Francisco, C., Cohuet, G., Vezzoli, S., Scuri, M., & Vestbo, J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31354-x · Cited by 425
Nici, L., Mammen, M. J., Charbek, E., Alexander, P. E., Au, D. H., Boyd, C. M., Criner, G. J., Donaldson, G. C., Dreher, M., Fan, V. S., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0625st · Cited by 316
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
Buhl, R., Maltais, F., Abrahams, R., Bjermer, L., Derom, E., Ferguson, G., Fležar, M., Hébert, J., McGarvey, L., Pizzichini, E., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00136014 · Cited by 315
Self-citationPrevention of Acute Exacerbations of COPD
Criner, G. J., Bourbeau, J., Diekemper, R. L., Ouellette, D. R., Goodridge, D., Hernandez, P., Curren, K., Balter, M. S., Bhutani, M., Camp, P. G., et al. (2015) · Chest · doi:10.1378/chest.14-1676 · Cited by 288
Metadata
- Authors
- Bateman, E. D., Ferguson, G. T., Barnes, N., Gallagher, N., Green, Y., Henley, M., & Banerji, D.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2013-05-30
- Volume
- 42
- Issue
- 6
- Pages
- 1484-1494
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2142449488
- Cited by
- 388
- References
- 27
- FWCI
- 43.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.